Valerie Cain
Nurse Practitioner · Eleanor, WVNPI 1861083305
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 340 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 42.6% of the total. Among nurse practitioner clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $14.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$527
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$437
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$268
- Amgen$252
- Pfizer$203
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,808100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 166 | $2,049 |
| Novo Nordisk | 37 | $527 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $437 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $268 |
| Amgen | 21 | $252 |
| Pfizer | 12 | $203 |
| Astellas Pharma US Inc | 7 | $133 |
| Lilly USA, LLC | 6 | $108 |
| Ironshore Pharmaceuticals Inc. | 5 | $83 |
| AstraZeneca | 6 | $82 |
| GSK | 5 | $81 |
| Exact Sciences | 4 | $80 |
| Echosens North America, Inc. | 1 | $76 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Shield Therapeutics Inc | 1 | $45 |
| Dexcom, Inc. | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Merck | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Novartis | 1 | $14 |
How this compares
$4,808 in reported general payments places this provider in the 95th percentile of 649 nurse practitioner providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $118,318 |
| JardianceEmpagliflozin | 56 | $88,059 |
| EliquisApixaban | 67 | $76,315 |
| JanuviaSitagliptin Phosphate | 51 | $66,750 |
| MounjaroTirzepatide | 51 | $66,128 |
| TrulicityDulaglutide | 53 | $62,849 |
| XareltoRivaroxaban | 21 | $33,663 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $21,030 |
| MyrbetriqMirabegron | 24 | $19,734 |
| LinzessLinaclotide | 13 | $16,076 |
| FarxigaDapagliflozin Propanediol | 14 | $14,847 |
| VascepaIcosapent Ethyl | 14 | $14,578 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $8,400 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,834 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $5,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $108 | $128,978104 claims |
| Novo NordiskOzempic | $527 | $118,318106 claims |
| Boehringer IngelheimJardiance | $15 | $88,05956 claims |
| PfizerEliquis | $203 | $76,31567 claims |
| MerckJanuvia | $20 | $66,75051 claims |
| Johnson & JohnsonXarelto | $15 | $33,66321 claims |
| AstraZenecaFarxiga, Symbicort | $82 | $21,68131 claims |
| GSKTrelegy Ellipta | $81 | $21,03011 claims |
| Astellas Pharma US IncMyrbetriq | $133 | $19,73424 claims |
| AbbVieLinzess | $2,049 | $16,07613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 649 nurse practitioner providers in West Virginia.
Other nurse practitioner in Eleanor
- Khristina LightEleanor$4K
- Leigh BrooksPrinceton$75K
- Destiny HowardBeckley$35K
- Rachael RigginsBeckley$19K
- Lacy HowardWheeling$18K
- Robin BlumeBeckley$18K
- Kellie VaughtBeckley$17K
- Lisa WalkerBeckley$17K
- Rachel BrillSouth Charleston$16K
- Kelly HughartSouth Charleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.